CCXI - ケモセントリックス （ChemoCentryx Inc.） ケモセントリックスCCXIのチャート
CCXIの企業情報
| symbol | CCXI |
|---|---|
| 会社名 | ChemoCentryx Inc. （ケモセントリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ケモセントリックス（ChemoCentryx Inc.）はバイオ医薬品会社であり、自己免疫疾患、炎症性疾患や癌を治療する経口投与の治療薬の発見・開発・商品化に従事する。薬物候補のそれぞれは、その負の炎症性または抑制性応答を選択的にブロックする特定の化学誘引物質受容体に焦点を当て、免疫系の残りの部分をそのまま残す。後期化合物には、Avacopan（CCX168）とCCX140が含まれる。アバコパン（CCX168）は、C5a受容体（C5aR）を標的とする経口投与補体阻害剤であり、抗好中球細胞質自己抗体関連血管炎（AAV）、非定型溶血性尿毒症症候群（aHUS）補体3糸球体症（C3G）を補完する。CCX140は、糖尿病性腎症（DN）、慢性腎疾患（CKD）及び局所分節性糸球体硬化症（FSGS）の開発において、C-Cケモカイン受容体2型（CCR2）として知られるケモカイン受容体の経口投与阻害剤である。 ケモセントリックスは米国のバイオ医薬品企業。自己免疫疾患、炎症性疾患、癌の治療向け経口治療薬の開発、商業化に従事。抗好中球細胞質抗体の治療薬CCX168、糖尿病性腎症治療薬CCX140、ケモカイン受容体向け経口阻害剤CCX872、中等症から重症のクロ―ン病治療薬Vercirnon、炎症性腸疾患向け阻害剤CCX507の製品候補を手掛ける。 ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. |
| 本社所在地 | 850 Maude Avenue Mountain View CA 94043 USA |
| 代表者氏名 | Thomas J. Schall トーマス・J・ショール |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-210-2900 |
| 設立年月日 | 1997年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2012年 |
| 従業員数 | 66人 |
| url | www.chemocentryx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ccxi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 15.48300 |
| 終値（lastsale） | 10.6 |
| 時価総額（marketcap） | 534012852.6 |
| 時価総額 | 時価総額（百万ドル） 574.81950 |
| 売上高 | 売上高（百万ドル） 89.89800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 407.47850 |
| 当期純利益 | 当期純利益（百万ドル） 16.80400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ChemoCentryx Inc revenues increased 43% to $24.6M. Net loss increased 7% to $16.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 34% to $32.5M (expense) General and administrative increase of 7% to $9.4M (expense). |
CCXIのテクニカル分析
CCXIのニュース
Amgen completes purchase of ChemoCentryx for $3.7 billion 2022/10/21 15:30:27 Business Journals
The deal includes FDA-approved Tavneos, a treatment for a group of autoimmune diseases that cause small vessel inflammation.
ChemoCentryx shareholders approve $4.7B merger with Amgen (NASDAQ:CCXI) 2022/10/18 21:45:49 Seeking Alpha
ChemoCentryx shareholders have overwhelmingly approved Amgen''s (AMGN) $3.7B acquisition of the company.
Amgen Stock Is Looking Interesting On The Dip (NASDAQ:AMGN) 2022/09/13 11:35:16 Seeking Alpha
Amgen continues to churn out respectable growth amidst a challenging economic backdrop. See why AMGN''s ChemoCentryx acquisition should bolster top-line growth.
7 Dow Stocks With Superior Fundamentals 2022/09/06 18:55:35 InvestorPlace
Today I’m writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices. The index serves as a bellwether that tracks investors’ sentiment. These large-cap, well-known companies are widely regarded as safe havens from market volatility. With their remarkable longevity and solid fundamentals, these companies tend to be among the first businesses to recover from economic uncertainties. So far in 2022, the DJIA has lost about 13.5% of its value. By comparison, the Nasdaq 100 index and the S&P 500 index have fallen around 25% and 18%, respectively, so far this year. Today’s list of Dow stocks to buy includes prominent blue-chip names that have sold off significantly in 2022. As investors continue to flock to safe bets, these Dow-30 members could be primed for significant rebounds throughout the rest of the year. Here are the seven Dow stocks to buy that offer compelling buying opportunities for patient investors.
ChemoCentryx''s Return On Capital Employed Insights 2022/09/01 14:20:27 Benzinga
According to data from Benzinga Pro, during Q2, ChemoCentryx ''s (NASDAQ: CCXI ) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. ChemoCentryx collected $5.46 million in revenue during Q1, but reported earnings showed a $38.61 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com
Amgen completes purchase of ChemoCentryx for $3.7 billion 2022/10/21 15:30:27 Business Journals
The deal includes FDA-approved Tavneos, a treatment for a group of autoimmune diseases that cause small vessel inflammation.
ChemoCentryx shareholders approve $4.7B merger with Amgen (NASDAQ:CCXI) 2022/10/18 21:45:49 Seeking Alpha
ChemoCentryx shareholders have overwhelmingly approved Amgen''s (AMGN) $3.7B acquisition of the company.
Amgen Stock Is Looking Interesting On The Dip (NASDAQ:AMGN) 2022/09/13 11:35:16 Seeking Alpha
Amgen continues to churn out respectable growth amidst a challenging economic backdrop. See why AMGN''s ChemoCentryx acquisition should bolster top-line growth.
7 Dow Stocks With Superior Fundamentals 2022/09/06 18:55:35 InvestorPlace
Today I’m writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices. The index serves as a bellwether that tracks investors’ sentiment. These large-cap, well-known companies are widely regarded as safe havens from market volatility. With their remarkable longevity and solid fundamentals, these companies tend to be among the first businesses to recover from economic uncertainties. So far in 2022, the DJIA has lost about 13.5% of its value. By comparison, the Nasdaq 100 index and the S&P 500 index have fallen around 25% and 18%, respectively, so far this year. Today’s list of Dow stocks to buy includes prominent blue-chip names that have sold off significantly in 2022. As investors continue to flock to safe bets, these Dow-30 members could be primed for significant rebounds throughout the rest of the year. Here are the seven Dow stocks to buy that offer compelling buying opportunities for patient investors.
ChemoCentryx''s Return On Capital Employed Insights 2022/09/01 14:20:27 Benzinga
According to data from Benzinga Pro, during Q2, ChemoCentryx ''s (NASDAQ: CCXI ) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. ChemoCentryx collected $5.46 million in revenue during Q1, but reported earnings showed a $38.61 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com
ChemoCentryx Q2 2022 Earnings Preview 2022/08/08 21:35:43 Seeking Alpha
ChemoCentryx (CCXI) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close
Earnings Preview: ChemoCentryx 2022/08/08 14:13:58 Benzinga
ChemoCentryx (NASDAQ: CCXI ) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here''s what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.49. ChemoCentryx bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
CHEMOCENTRYX, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CCXI and Encourages Investors to Contact the Firm 2022/08/08 00:05:00 GlobeNewswire
NEW YORK, Aug. 07, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of ChemoCentryx, Inc. (NASDAQ: CCXI) (“ChemoCentryx”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Amgen (NASDAQ: AMGN) (“Amgen”).
Is Now A Good Time To Invest In ChemoCentryx Inc. (NASDAQ: CCXI)? 2022/08/05 17:00:00 Stocks Register
ChemoCentryx Inc. (NASDAQ:CCXI) shares, rose in value on Friday, August 05, with the stock price up by 0.18% to the previous day’s close as strong demand from buyers drove the stock to $50.52. Actively observing the price movement in the recent trading, the stock is buoying the session at $50.43, falling within a range of … Is Now A Good Time To Invest In ChemoCentryx Inc. (NASDAQ: CCXI)? Read More »
Amgen bets on ChemoCentryx’s rare disease drug in $3.7 billion deal 2022/08/05 12:05:13 Express Pharma
Amgen has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for the therapy are expected to expire in 2029 The post Amgen bets on ChemoCentryx’s rare disease drug in $3.7 billion deal appeared first on Express Pharma .